

August 16, 2004

For more information, contact:
Dr. Peter Bick, CEO CogState Ltd 0408 415 823

**CogState signs deal with US Centers
for Disease Control (CDC) for HIV Dementia Trial**

Melbourne, August 13, 2004 - CogState Ltd (ASX:CGS) has signed a deal with the US Government agency - The Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia to use the CogState computer-based cognitive test in a large prospective trial in patients with HIV to spot early signs of HIV-related dementia. The CDC - the world's largest federal agency for disease prevention and control. As nearly 40% of HIV patients show a decline in brain function characterized by loss of initiative and motivation to cope with the demands of everyday life, early identification of these individuals could result in improved quality-of-life.

CogState Ltd. CEO, Dr. Peter Bick commented "It is hard to overstate the importance of this win for the company because US government agencies are obligated to first review US products. In searching for a the best tool to accurately measure changes in brain function (cognition) over time, and which had no cultural or language bias, the CDC chose CogState, demonstrating to the world that our technology is superior to anything available in the US. The \$21,000 value of the deal is useful, but the true value is in the credibility it bestows for us in the largest market in the world, the US".

"The sentiment of the CDC was recently echoed by Schutt Sports, the #1 gridiron football manufacturer in the US, who choose CogState as a partner to make Concussion Sentinel™ available to every high school and college in the US. We are a small but these deals point-out to the discerning that we are on the right track to build a robust sales pipeline" added Dr. Bick.

About CogState

CogState Ltd. was established in 1999 with headquarters in Melbourne, Australia. In February 2004 the company listed on the Australian Stock Exchange (ASX) as "CGS." The company specializes in neuroscience, particularly in the development and commercialization of computer-based tests for neurodegenerative disorders such as Alzheimer's and Parkinson's disease and concussion-related injury. A division of the company, CogSport, marketed in the U.S. as Concussion Sentinel, is a novel concussion management tool developed to aid physicians in

making confident return-to-play decisions after an athlete has suffered a concussion.

Concussion Sentinel is applicable for use by sporting organizations, medical professionals, and parents/athletes and provides rapid measurement of cognitive function. Other divisions of the company focus on providing computer-based measurement tools to pharmaceutical companies for use during clinical trials.

For more information please visit: www.cogstate.com